Intrinsic value of CAS Medical Systems, Inc. - CASM

Previous Close

$2.44

  Intrinsic Value

$1.17

stock screener

  Rating & Target

str. sell

-52%

Previous close

$2.44

 
Intrinsic value

$1.17

 
Up/down potential

-52%

 
Rating

str. sell

We calculate the intrinsic value of CASM stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  18.90
  17.51
  16.26
  15.13
  14.12
  13.21
  12.39
  11.65
  10.98
  10.39
  9.85
  9.36
  8.93
  8.53
  8.18
  7.86
  7.58
  7.32
  7.09
  6.88
  6.69
  6.52
  6.37
  6.23
  6.11
  6.00
  5.90
  5.81
  5.73
  5.65
Revenue, $m
  23
  27
  31
  36
  41
  46
  52
  58
  64
  71
  78
  85
  92
  100
  108
  117
  126
  135
  145
  155
  165
  176
  187
  198
  211
  223
  236
  250
  264
  279
Variable operating expenses, $m
  9
  11
  13
  15
  17
  19
  21
  24
  26
  29
  32
  35
  38
  41
  45
  48
  52
  55
  59
  63
  68
  72
  77
  81
  86
  92
  97
  103
  109
  115
Fixed operating expenses, $m
  17
  18
  18
  19
  19
  19
  20
  20
  21
  21
  22
  22
  23
  23
  24
  24
  25
  25
  26
  26
  27
  27
  28
  29
  29
  30
  31
  31
  32
  33
Total operating expenses, $m
  26
  29
  31
  34
  36
  38
  41
  44
  47
  50
  54
  57
  61
  64
  69
  72
  77
  80
  85
  89
  95
  99
  105
  110
  115
  122
  128
  134
  141
  148
Operating income, $m
  -4
  -2
  0
  2
  5
  7
  10
  14
  17
  20
  24
  28
  32
  36
  40
  45
  50
  54
  60
  65
  70
  76
  82
  88
  95
  102
  109
  116
  124
  132
EBITDA, $m
  -3
  -1
  1
  3
  6
  9
  12
  15
  19
  23
  26
  30
  35
  39
  43
  48
  53
  58
  64
  69
  75
  81
  87
  94
  101
  108
  116
  123
  132
  140
Interest expense (income), $m
  1
  1
  1
  2
  2
  2
  2
  3
  3
  3
  4
  4
  4
  5
  5
  6
  6
  7
  7
  8
  8
  9
  9
  10
  11
  11
  12
  13
  13
  14
  15
Earnings before tax, $m
  -5
  -4
  -2
  0
  3
  5
  8
  11
  14
  17
  20
  23
  27
  31
  35
  39
  43
  47
  52
  57
  62
  67
  72
  78
  84
  90
  96
  103
  110
  117
Tax expense, $m
  0
  0
  0
  0
  1
  1
  2
  3
  4
  4
  5
  6
  7
  8
  9
  10
  12
  13
  14
  15
  17
  18
  19
  21
  23
  24
  26
  28
  30
  32
Net income, $m
  -5
  -4
  -2
  0
  2
  4
  6
  8
  10
  12
  15
  17
  20
  22
  25
  28
  31
  35
  38
  41
  45
  49
  53
  57
  61
  65
  70
  75
  80
  85

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  12
  14
  16
  18
  21
  23
  26
  29
  33
  36
  40
  43
  47
  51
  55
  60
  64
  69
  74
  79
  84
  90
  95
  101
  107
  114
  121
  128
  135
  143
Adjusted assets (=assets-cash), $m
  12
  14
  16
  18
  21
  23
  26
  29
  33
  36
  40
  43
  47
  51
  55
  60
  64
  69
  74
  79
  84
  90
  95
  101
  107
  114
  121
  128
  135
  143
Revenue / Adjusted assets
  1.917
  1.929
  1.938
  2.000
  1.952
  2.000
  2.000
  2.000
  1.939
  1.972
  1.950
  1.977
  1.957
  1.961
  1.964
  1.950
  1.969
  1.957
  1.959
  1.962
  1.964
  1.956
  1.968
  1.960
  1.972
  1.956
  1.950
  1.953
  1.956
  1.951
Average production assets, $m
  3
  4
  4
  5
  6
  7
  7
  8
  9
  10
  11
  12
  13
  15
  16
  17
  18
  20
  21
  22
  24
  25
  27
  29
  31
  32
  34
  36
  38
  41
Working capital, $m
  2
  3
  3
  4
  4
  5
  5
  6
  7
  7
  8
  9
  10
  10
  11
  12
  13
  14
  15
  16
  17
  18
  19
  21
  22
  23
  25
  26
  27
  29
Total debt, $m
  9
  11
  13
  14
  16
  19
  21
  23
  26
  29
  31
  34
  37
  40
  44
  47
  51
  54
  58
  62
  66
  71
  75
  80
  85
  90
  95
  101
  106
  112
Total liabilities, $m
  9
  11
  12
  14
  16
  18
  21
  23
  26
  28
  31
  34
  37
  40
  44
  47
  51
  54
  58
  62
  66
  71
  75
  80
  85
  90
  95
  101
  106
  112
Total equity, $m
  2
  3
  3
  4
  4
  5
  6
  6
  7
  8
  8
  9
  10
  11
  12
  13
  14
  15
  16
  17
  18
  19
  20
  21
  23
  24
  26
  27
  29
  30
Total liabilities and equity, $m
  11
  14
  15
  18
  20
  23
  27
  29
  33
  36
  39
  43
  47
  51
  56
  60
  65
  69
  74
  79
  84
  90
  95
  101
  108
  114
  121
  128
  135
  142
Debt-to-equity ratio
  3.770
  3.760
  3.750
  3.750
  3.740
  3.740
  3.740
  3.740
  3.730
  3.730
  3.730
  3.730
  3.730
  3.730
  3.730
  3.730
  3.730
  3.730
  3.720
  3.720
  3.720
  3.720
  3.720
  3.720
  3.720
  3.720
  3.720
  3.720
  3.720
  3.720
Adjusted equity ratio
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212
  0.212

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -5
  -4
  -2
  0
  2
  4
  6
  8
  10
  12
  15
  17
  20
  22
  25
  28
  31
  35
  38
  41
  45
  49
  53
  57
  61
  65
  70
  75
  80
  85
Depreciation, amort., depletion, $m
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  4
  4
  4
  4
  5
  5
  5
  6
  6
  6
  7
  7
  8
  8
Funds from operations, $m
  -4
  -3
  -1
  2
  3
  5
  7
  10
  12
  14
  17
  20
  22
  25
  28
  32
  35
  38
  42
  46
  50
  54
  58
  62
  67
  72
  77
  82
  88
  94
Change in working capital, $m
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
Cash from operations, $m
  -5
  -3
  -1
  1
  3
  5
  7
  9
  11
  14
  16
  19
  22
  25
  28
  31
  34
  37
  41
  45
  49
  53
  57
  61
  66
  71
  76
  81
  86
  92
Maintenance CAPEX, $m
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -6
  -6
  -6
  -7
  -7
  -8
New CAPEX, $m
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
Cash from investing activities, $m
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -5
  -7
  -7
  -7
  -8
  -8
  -8
  -9
  -9
  -10
Free cash flow, $m
  -6
  -4
  -2
  -1
  1
  3
  5
  7
  9
  11
  13
  16
  18
  21
  23
  26
  29
  32
  36
  39
  43
  46
  50
  54
  58
  63
  67
  72
  77
  82
Issuance/(repayment) of debt, $m
  1
  2
  2
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
  6
Issuance/(repurchase) of shares, $m
  6
  4
  2
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  7
  6
  4
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  6
  6
  6
Total cash flow (excl. dividends), $m
  2
  1
  1
  2
  3
  5
  7
  9
  11
  14
  16
  18
  21
  24
  27
  30
  33
  36
  40
  43
  47
  51
  55
  59
  63
  68
  73
  77
  83
  88
Retained Cash Flow (-), $m
  -6
  -4
  -2
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -4
  -3
  -1
  1
  3
  4
  6
  8
  11
  13
  15
  18
  20
  23
  26
  29
  32
  35
  39
  42
  46
  50
  53
  58
  62
  66
  71
  76
  81
  87
Discount rate, %
  6.90
  7.25
  7.61
  7.99
  8.39
  8.81
  9.25
  9.71
  10.19
  10.70
  11.24
  11.80
  12.39
  13.01
  13.66
  14.34
  15.06
  15.81
  16.61
  17.44
  18.31
  19.22
  20.18
  21.19
  22.25
  23.37
  24.53
  25.76
  27.05
  28.40
PV of cash for distribution, $m
  -4
  -2
  -1
  1
  2
  3
  3
  4
  4
  5
  5
  5
  4
  4
  4
  3
  3
  3
  2
  2
  1
  1
  1
  1
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  78.2
  67.1
  62.5
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1
  62.1

CAS Medical Systems, Inc. is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products for patient care. The Company designs, manufactures and distributes the FORE-SIGHT and FORE-SIGHT ELITE brand tissue oximeters and sensors. It operates through Tissue Oximetry Monitoring, which includes sales of its FORE-SIGHT tissue oximeter monitors, sensors and accessories. The FORE-SIGHT Tissue Oximeter technology provides clinicians a non-invasive, quantitative measurement of oxygenation in cerebral tissue.

FINANCIAL RATIOS  of  CAS Medical Systems, Inc. (CASM)

Valuation Ratios
P/E Ratio -22.2
Price to Sales 3
Price to Book 22.2
Price to Tangible Book
Price to Cash Flow -16.7
Price to Free Cash Flow -13.3
Growth Rates
Sales Growth Rate 15.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate 0%
Financial Strength
Quick Ratio 5
Current Ratio 0.5
LT Debt to Equity 200%
Total Debt to Equity 233.3%
Interest Coverage -5
Management Effectiveness
Return On Assets -13.5%
Ret/ On Assets - 3 Yr. Avg. -33.4%
Return On Total Capital -26.1%
Ret/ On T. Cap. - 3 Yr. Avg. -47.9%
Return On Equity -66.7%
Return On Equity - 3 Yr. Avg. -118.5%
Asset Turnover 1.4
Profitability Ratios
Gross Margin 54.5%
Gross Margin - 3 Yr. Avg. 51.5%
EBITDA Margin -18.2%
EBITDA Margin - 3 Yr. Avg. -25.4%
Operating Margin -22.7%
Oper. Margin - 3 Yr. Avg. -32.1%
Pre-Tax Margin -27.3%
Pre-Tax Margin - 3 Yr. Avg. -35.4%
Net Profit Margin -13.6%
Net Profit Margin - 3 Yr. Avg. -30.9%
Effective Tax Rate 16.7%
Eff/ Tax Rate - 3 Yr. Avg. 9.7%
Payout Ratio 0%

CASM stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CASM stock intrinsic value calculation we used $19 million for the last fiscal year's total revenue generated by CAS Medical Systems, Inc.. The default revenue input number comes from 0001 income statement of CAS Medical Systems, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CASM stock valuation model: a) initial revenue growth rate of 18.9% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6.9%, whose default value for CASM is calculated based on our internal credit rating of CAS Medical Systems, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of CAS Medical Systems, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CASM stock the variable cost ratio is equal to 42.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $17 million in the base year in the intrinsic value calculation for CASM stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 14.1% for CAS Medical Systems, Inc..

Corporate tax rate of 27% is the nominal tax rate for CAS Medical Systems, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CASM stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CASM are equal to 14.5%.

Life of production assets of 3.1 years is the average useful life of capital assets used in CAS Medical Systems, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CASM is equal to 10.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2.512989 million for CAS Medical Systems, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 28.198 million for CAS Medical Systems, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of CAS Medical Systems, Inc. at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
BABY Natus Medical 23.97 4.61  str.sell
NURO NeuroMetrix, I 0.535 0.20  str.sell
MASI Masimo Corpora 141.08 57.20  str.sell
NVTR Nuvectra Corpo 3.71 1.23  str.sell
IART Integra LifeSc 50.88 25.16  str.sell
UTMD Utah Medical P 80.61 66.18  sell
BDX Becton, Dickin 234.16 396.45  str.buy

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.